尽管免疫疗法取得了巨大成功，在实际应用中仍面临许多挑战。先前的研究发现，家族序列相似性110A成员（FAM110A）参与细胞周期的调节，在胰腺癌中发挥致癌作用。然而，FAM110A在泛癌中的预测价值以及其在免疫应答中的参与仍不清楚。本研究使用Human Protein Atlas数据库检测了FAM110A在人类正常组织中的表达情况，使用Tumor Immune Estimation Resource和TIMER 2.0数据库探究了FAM110A表达与免疫检查点基因和免疫浸润的关联，使用Gene Set Cancer Analysis数据库探讨了FAM110A表达与拷贝数变异和甲基化的相关性。使用LinkedOmics数据库进行基因本体论和京都基因与基因组百科全书通路富集分析。统计分析和数据可视化使用R软件（版本3.6.3）从The Cancer Genome Atlas或Genotype-Tissue Expression数据库获得。通过免疫组织化学验证了临床样本。相对于正常组织，FAM110A表达在大多数肿瘤组织中升高。拷贝数变异和甲基化与肿瘤组织中异常FAM110A mRNA表达相关。FAM110A影响预后并与多个免疫检查点基因的表达以及多种类型的癌症中的肿瘤浸润免疫细胞丰度相关，尤其是在肝细胞腺癌中。FAM110A相关基因参与了肝细胞腺癌中的多个免疫相关过程。FAM110A参与调节免疫浸润，并在多种癌症中影响患者的预后，尤其是在肝细胞腺癌中，可作为人类癌症的预后和免疫生物标记。Copyright © 2023 Zhong, Shi, Wen, Chen, Li, Ruan, Zeng, Dai, Xiong, Li, Lei and Deng.

Despite great success, immunotherapy still faces many challenges in practical applications. It was previously found that family with sequence similarity 110 member A (FAM110A) participate in the regulation of the cell cycle and plays an oncogenic role in pancreatic cancer. However, the prognostic value of FAM110A in pan-cancer and its involvement in immune response remain unclear.The Human Protein Atlas (HPA) database was used to detect the expression of FAM110A in human normal tissues, the Tumor Immune Estimation Resource (TIMER) and TIMER 2.0 databases were used to explore the association of FAM110A expression with immune checkpoint genes and immune infiltration, and the Gene Set Cancer Analysis (GSCA) database was used to explore the correlation between FAM110A expression and copy number variations (CNV) and methylation. The LinkedOmics database was used for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Statistical analysis and visualization of data from the The Cancer Genome Atlas (TCGA) or the Genotype-Tissue Expression (GTEx) databases were performed using the R software (version 3.6.3). Clinical samples were validated using immunohistochemistry.FAM110A expression was elevated in most tumor tissues compared with that in normal tissues. CNV and methylation were associated with abnormal FAM110A mRNA expression in tumor tissues. FAM110A affected prognosis and was associated with the expression of multiple immune checkpoint genes and abundance of tumor-infiltrating immune cells across multiple types of cancer, especially in liver hepatocellular carcinoma (LIHC). FAM110A-related genes were involved in multiple immune-related processes in LIHC.FAM110A participates in regulating the immune infiltration and affecting the prognosis of patients in multiple cancers, especially in LIHC. FAM110A may serve as a prognostic and immunological biomarker for human cancer.Copyright © 2023 Zhong, Shi, Wen, Chen, Li, Ruan, Zeng, Dai, Xiong, Li, Lei and Deng.